Compare Mercadolibre Inc (MELI) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Mercadolibre Inc trades at $1,823.73 (market cap $95.11B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Mercadolibre Inc is far larger — about 19.5× Travere Therapeutics Inc. Common Stock's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Travere Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 118 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MELI | TVTX | |
|---|---|---|
Market Cap | $95.11B | $4.88B |
Volume | 242,115 | 1,668,577 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $67.52 |
52-Week Low | $1.55K | $26.79 |
Typical Hold Time | 118 Days | 0 Days |
Enterprise Value | $102.76B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,839.11, down 2.82% on the day, amid a bullish technical setup and strong analyst support. The stock shows robust revenue growth, with 2025 sales reaching $28.89 billion, though net income margins have softened. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy services, while its fintech credit portfolio surged 75% in Q2 2026.
Outlook remains positive given dominant Latin American e-commerce and fintech positioning, but risks include macroeconomic pressures in key markets like Argentina and elevated valuation multiples. Wall Street consensus is strongly bullish with a $2,160 price target, though profit trends warrant monitoring for sustained shareholder returns.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
